The Food and Drug Administration on Monday granted marketing clearance to Arymo ER, a tamper-resistant pain-relief medicine developed by Egalet Corp.
Arymo ER, which contains morphine sulfate, was approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
The approval triggered $40 million in new funding for Egalet (NASDAQ: EGLT) from the second tranche of a debt financing…
The Food and Drug Administration on Monday granted marketing clearance to Arymo ER, a tamper-resistant pain-relief medicine developed by Egalet Corp.
Arymo ER, which contains morphine sulfate, was approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
The approval triggered $40 million in new funding for Egalet (NASDAQ: EGLT) from the second tranche of a debt financing…